Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
The article discusses recent analyst ratings for Apellis Pharmaceuticals (NASDAQ:APLS), highlighting a range of opinions from bullish to bearish. Over the past three months, 18 analysts have provided ratings, with the majority being bullish or somewhat bullish. The average 12-month price target has decreased from $76.47 to $71.89. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Apellis Pharmaceuticals has shown significant revenue growth but faces challenges with profitability and financial risk due to high debt levels.
October 16, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals has received mixed analyst ratings, with a decrease in the average price target from $76.47 to $71.89. Despite strong revenue growth, the company faces challenges with profitability and high debt levels.
The article provides a detailed analysis of analyst ratings for Apellis Pharmaceuticals, showing a decrease in the average price target and mixed sentiments. The company's strong revenue growth is offset by challenges in profitability and high debt levels, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100